Improving Gene Editing by Manipulating DNA Repair | Daniel Durocher

Added:

Genomic Instability Risks and the Paradigm Shift to Double-Strand Break-Free Editing

While inhibiting 53BP1 successfully biases cells toward homology-directed repair (HDR), suppressing key DNA damage response (DDR) pathways poses significant safety concerns. 53BP1 acts as a crucial tumor suppressor; its transient inhibition can lead to genomic instability, chromosomal rearrangements, and an increased risk of oncogenic transformation, making clinical translation risky. Consequently, a major counter-perspective argues against manipulating endogenous double-strand break (DSB) repair machinery altogether. Instead, many researchers advocate for 'DSB-free' technologies like Base Editing and Prime Editing. These approaches enable precise genomic modifications without generating double-strand breaks or relying on the cell's hazardous HDR/NHEJ repair pathways, bypassing the need for potentially dangerous interventions in the host cell's DNA damage response network.

Understanding the mechanics of CRISPR-Cas9, specifically how the Cas9 enzyme induces targeted double-strand breaks (DSBs) in genomic DNA.
Knowledge of the endogenous DNA double-strand break repair pathways, specifically the competition between error-prone Non-Homologous End Joining (NHEJ) and template-directed Homology-Directed Repair (HDR).
Familiarity with the biological role of 53BP1 as a key protein regulator that promotes NHEJ and actively suppresses HDR at DSB sites.
Basic concepts of protein engineering, particularly how scaffold proteins or ubiquitin variants (UbVs) can be designed to inhibit specific protein-protein interactions.
Exploring the translation of HDR-boosting technologies into clinical gene therapies for monogenic diseases that require precise gene correction rather than gene disruption.
Investigating the long-term safety, genomic stability, and potential off-target or oncogenic risks of temporarily disabling central DNA repair regulators like 53BP1.
Studying advanced delivery vehicles (such as lipid nanoparticles, virus-like particles, or ribonucleoprotein complexes) to transiently introduce engineered ubiquitin variants into target stem cells.
Comparing the efficacy, precision, and application limitations of HDR enhancement strategies with next-generation, double-strand break-free technologies like base editors and prime editors.
1.1K views6likes30:37@GairdnerAwardsOriginal Release: 2016-12-01

DNA repair pathways, particularly the competition between non-homologous end joining (NHEJ) and homology-directed repair (HDR), determine the outcome of CRISPR-Cas9 gene editing. The protein 53BP1 acts as a central regulator that suppresses HDR by inhibiting DNA end resection and BRCA1 recruitment. By developing a genetically encoded ubiquitin variant (I53) that specifically binds and inhibits 53BP1, researchers can shift the balance toward HDR, thereby improving the precision of gene editing reactions. This approach can be combined with other manipulations (such as RNF168 inhibition and CtIP activation) to potentially activate HDR in non-dividing cells, which is crucial for therapeutic applications.